Literature DB >> 33927387

Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins.

Ha V Dang1, Robert W Cross2,3, Viktoriya Borisevich2, Zachary A Bornholdt4, Brandyn R West4, Yee-Peng Chan5, Chad E Mire2,3, Sofia Cheliout Da Silva5, Antony S Dimitrov5, Lianying Yan5, Moushimi Amaya5, Chanakha K Navaratnarajah6, Larry Zeitlin4, Thomas W Geisbert2,3, Christopher C Broder5, David Veesler7.   

Abstract

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses (HNVs) causing respiratory illness and severe encephalitis in humans, with fatality rates of 50-100%. There are no licensed therapeutics or vaccines to protect humans. HeV and NiV use a receptor-binding glycoprotein (G) and a fusion glycoprotein (F) to enter host cells. HNV F and G are the main targets of the humoral immune response, and the presence of neutralizing antibodies is a correlate of protection against NiV and HeV in experimentally infected animals. We describe here two cross-reactive F-specific antibodies, 1F5 and 12B2, that neutralize NiV and HeV through inhibition of membrane fusion. Cryo-electron microscopy structures reveal that 1F5 and 12B2 recognize distinct prefusion-specific, conserved quaternary epitopes and lock F in its prefusion conformation. We provide proof-of-concept for using antibody cocktails for neutralizing NiV and HeV and define a roadmap for developing effective countermeasures against these highly pathogenic viruses.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33927387     DOI: 10.1038/s41594-021-00584-8

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  73 in total

Review 1.  Nipah virus: transmission of a zoonotic paramyxovirus.

Authors:  Bronwyn Anne Clayton
Journal:  Curr Opin Virol       Date:  2017-01-11       Impact factor: 7.090

2.  Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus.

Authors:  Matthew I Bonaparte; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Bruce A Mungall; Kimberly A Bishop; Vidita Choudhry; Dimiter S Dimitrov; Lin-Fa Wang; Bryan T Eaton; Christopher C Broder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

3.  EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus.

Authors:  Oscar A Negrete; Ernest L Levroney; Hector C Aguilar; Andrea Bertolotti-Ciarlet; Ronen Nazarian; Sara Tajyar; Benhur Lee
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

Review 4.  Receptor-mediated cell entry of paramyxoviruses: Mechanisms, and consequences for tropism and pathogenesis.

Authors:  Chanakha K Navaratnarajah; Alex R Generous; Iris Yousaf; Roberto Cattaneo
Journal:  J Biol Chem       Date:  2020-01-16       Impact factor: 5.157

Review 5.  Epidemiology of henipavirus disease in humans.

Authors:  Stephen P Luby; Emily S Gurley
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

6.  Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2.

Authors:  Thomas A Bowden; A Radu Aricescu; Robert J C Gilbert; Jonathan M Grimes; E Yvonne Jones; David I Stuart
Journal:  Nat Struct Mol Biol       Date:  2008-05-18       Impact factor: 15.369

7.  Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3.

Authors:  Kai Xu; Kanagalaghatta R Rajashankar; Yee-Peng Chan; Juha P Himanen; Christopher C Broder; Dimitar B Nikolov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-16       Impact factor: 11.205

8.  Evidence for henipavirus spillover into human populations in Africa.

Authors:  Olivier Pernet; Bradley S Schneider; Shannon M Beaty; Matthew LeBreton; Tatyana E Yun; Arnold Park; Trevor T Zachariah; Thomas A Bowden; Peta Hitchens; Christina M Ramirez; Peter Daszak; Jonna Mazet; Alexander N Freiberg; Nathan D Wolfe; Benhur Lee
Journal:  Nat Commun       Date:  2014-11-18       Impact factor: 14.919

9.  Convergence of Humans, Bats, Trees, and Culture in Nipah Virus Transmission, Bangladesh.

Authors:  Emily S Gurley; Sonia T Hegde; Kamal Hossain; Hossain M S Sazzad; M Jahangir Hossain; Mahmudur Rahman; M A Yushuf Sharker; Henrik Salje; M Saiful Islam; Jonathan H Epstein; Salah U Khan; A Marm Kilpatrick; Peter Daszak; Stephen P Luby
Journal:  Emerg Infect Dis       Date:  2017-09       Impact factor: 6.883

Review 10.  Hendra and Nipah viruses: different and dangerous.

Authors:  Bryan T Eaton; Christopher C Broder; Deborah Middleton; Lin-Fa Wang
Journal:  Nat Rev Microbiol       Date:  2006-01       Impact factor: 60.633

View more
  8 in total

1.  Nipah amidst Covid-19 Pandemic, another Re-Emerging Infectious Disease of Pandemic Potential - a Narrative Review.

Authors:  Ariyanachi Kaliappan; Vanangamudi Kaliappan; Jyothi Tadi Lakshmi; S Raja; Shalam Shireen Nikhat; Meena S Vidya; Mallamgunta Saranya; Triveni Sagar; Kesavulu Dara Chenna
Journal:  Maedica (Bucur)       Date:  2022-06

2.  Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant.

Authors:  Zhaoqian Wang; Ha V Dang; Moushimi Amaya; Yan Xu; Randy Yin; Lianying Yan; Andrew C Hickey; Edward J Annand; Bethany A Horsburgh; Peter A Reid; Ina Smith; John-Sebastian Eden; Kai Xu; Christopher C Broder; David Veesler
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-26       Impact factor: 12.779

3.  An Immunoinformatics Prediction of Novel Multi-Epitope Vaccines Candidate Against Surface Antigens of Nipah Virus.

Authors:  Md Mahfuzur Rahman; Joynob Akter Puspo; Ahmed Ahsan Adib; Mohammad Enayet Hossain; Mohammad Mamun Alam; Sharmin Sultana; Ariful Islam; John D Klena; Joel M Montgomery; Syed M Satter; Tahmina Shirin; Mohammed Ziaur Rahman
Journal:  Int J Pept Res Ther       Date:  2022-06-23       Impact factor: 2.191

4.  Novel Hendra Virus Variant Detected by Sentinel Surveillance of Horses in Australia.

Authors:  Edward J Annand; Bethany A Horsburgh; Kai Xu; Peter A Reid; Ben Poole; Maximillian C de Kantzow; Nicole Brown; Alison Tweedie; Michelle Michie; John D Grewar; Anne E Jackson; Nagendrakumar B Singanallur; Karren M Plain; Karan Kim; Mary Tachedjian; Brenda van der Heide; Sandra Crameri; David T Williams; Cristy Secombe; Eric D Laing; Spencer Sterling; Lianying Yan; Louise Jackson; Cheryl Jones; Raina K Plowright; Alison J Peel; Andrew C Breed; Ibrahim Diallo; Navneet K Dhand; Philip N Britton; Christopher C Broder; Ina Smith; John-Sebastian Eden
Journal:  Emerg Infect Dis       Date:  2022-03       Impact factor: 6.883

Review 5.  Henipavirus Immune Evasion and Pathogenesis Mechanisms: Lessons Learnt from Natural Infection and Animal Models.

Authors:  Philip Lawrence; Beatriz Escudero-Pérez
Journal:  Viruses       Date:  2022-04-29       Impact factor: 5.818

Review 6.  Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses.

Authors:  Mireia Pelegrin; Soledad Marsile-Medun; Daouda Abba-Moussa; Manon Souchard; Mar Naranjo-Gomez
Journal:  Antibodies (Basel)       Date:  2022-07-26

7.  A platform technology for generating subunit vaccines against diverse viral pathogens.

Authors:  Andrew Young; Ariel Isaacs; Connor A P Scott; Naphak Modhiran; Christopher L D McMillan; Stacey T M Cheung; Jennifer Barr; Glenn Marsh; Nazia Thakur; Dalan Bailey; Kenneth S M Li; Hayes K H Luk; Kin-Hang Kok; Susanna K P Lau; Patrick C Y Woo; Wakako Furuyama; Andrea Marzi; Paul R Young; Keith J Chappell; Daniel Watterson
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

8.  Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.

Authors:  Rebecca J Loomis; Anthony T DiPiazza; Samantha Falcone; Tracy J Ruckwardt; Kaitlyn M Morabito; Olubukola M Abiona; Lauren A Chang; Ria T Caringal; Vladimir Presnyak; Elisabeth Narayanan; Yaroslav Tsybovsky; Deepika Nair; Geoffrey B Hutchinson; Guillaume B E Stewart-Jones; Lisa A Kueltzo; Sunny Himansu; John R Mascola; Andrea Carfi; Barney S Graham
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.